Optima London PCI 2024 - On Demand
Published: 04 October 2024
-
Views:
88
-
Likes:
7
-
Views:
88
-
Likes:
7
-
Up Next -
11m 38sPart 2 | Session 2 Understanding Angina = Optimising Treatment
-
18m 11sPart 2 | Session 3 What Role Does Mindset Play in Treatment Response?
-
18m 4s
-
1h 15m 25sPart 2 | Session 5 Live Cases: Aarhus, Denmark | Aalst, Belgium
-
36m 4sPart 2 | Session 6 Debate: Microvascular Function Is a Waste of Time
-
31m 48s
-
25m 8sPart 3 | Session 2 Eccentric Calcium - The Hidden Hazard?
-
13m 20sPart 3 | Session 3 Ready to Stent? How to Assess Calcium Modification
-
23m 11s
-
1h 29m 28sPart 3 | Session 5 Live Cases: St Georges, UK | Bristol Heart, UK
-
6m 2sPart 3 | Session 6 Close Reflections
-
3m 43sPart 4 | Session 1 Welcome and Introduction
-
21m 43sPart 4 | Session 2 How Expanding Your Complex Skills Can Help More Widely
-
15m 25sPart 4 | Session 3 The Role of DCBs in Treating CTO & Complex CAD
-
19m 24s
-
1h 16m 36sPart 4 | Session 5 Live Cases: Aalst, Belgium | St Georges, UK
-
34m 43sPart 4 | Session 6 Debate: DCB – Are They Ready for Primetime?
-
35m 23sPart 5 | Session 1 Debate: OCT vs IVUS: My Choice Is Best
-
23m 55sPart 5 | Session 2 Interactive Live Case Planning: New Technology Showcase
-
1h 27m 42sPart 5 | Session 3 Live cases: Bristol Heart, UK | Humanitas Milan, Italy
-
26m 31sPart 5 | Session 4 Reducing Variability, to Ensure the Best Results for Patients
-
17m 59sPart 5 | Session 5 Is Vulnerable Plaque a Valid Target?
-
1m 55sPart 1 | Session 1 Angina Does the Patient Come First? James Spratt, Sanjog Kalra, Carlos Collet, Colm Hanratty, Ziad A Ali, Rasha Al-Lamee, Margaret McEntegart, Kevin Croce, Jonathan Hill
-
2m 1sPart 1 | Session 2 Calcium Management Is One Option Enough? James Spratt, Sanjog Kalra, Carlos Collet, Colm Hanratty, Ziad A Ali, Rasha Al-Lamee, Margaret McEntegart, Kevin Croce, Jonathan Hill
-
2m 9sPart 1 | Session 3 Complex PCI CTO the New Norm? James Spratt, Sanjog Kalra, Carlos Collet, Colm Hanratty, Ziad A Ali, Rasha Al-Lamee, Margaret McEntegart, Kevin Croce, Jonathan Hill
-
1m 31sPart 1 | Session 4 Time to Focus On Patient-Oriented Goals? James Spratt, Sanjog Kalra, Carlos Collet, Colm Hanratty, Ziad A Ali, Rasha Al-Lamee, Margaret McEntegart, Kevin Croce, Jonathan Hill
-
3m 29sPart 1 | Session 5 What Is the Future Standard of Care? James Spratt, Sanjog Kalra, Carlos Collet, Colm Hanratty, Ziad A Ali, Rasha Al-Lamee, Margaret McEntegart, Kevin Croce, Jonathan Hill
Overview
Radcliffe are delighted to partner with Optima Education to offer on-demand access to the Optima London PCI 2024 event.
Optima London PCI 2024 was held on 7 and 8 October 2024.
The event featured over 40 expert faculty members and focused on four key complex, high-risk intervention topics: angina, calcium management, complex PCI/CTO and future standards of care. The programme included live case demonstrations, hands-on sessions, and expert debates, offering participants deep insights into patient-centred care, cutting-edge technologies, and advanced procedural planning.
At Optima, we believe that education is central to patient care. Our unique approach is designed to help you develop the thinking, skills and knowledge to optimise patient care. We clarify and simplify clinical messaging into engaging and accessible content. Our values of quality, simplicity and innovation are central to this vision.
Optima would like to thank:
Sponsors: Abbott, Asahi Intecc, Boston Scientific, Cordis, CryoTherapeutics, Elixir, GE HealthCare, HeartFlow, Medtronic, Rampart, Seigla Medical, Shockwave Medical, VP Med Group
Scientific Partner: OPCI, CoreAalst
Hospital Partners: HCA Healthcare
Target Audience
- Interventional Cardiologists
- Interventional Cardiology Nurses
- Cathlab Personnel
- Interventional Fellows
More from this programme
Part 1
Optima London PCI 2024 -Interviews
Part 2
Day 1 - Session 1: Angina
Part 3
Day 1 - Session 2: Calcium Management
Part 4
Day 2 - Session 3: Complex PCI/CTO
Part 5
Day 2 - Session 4: What Does the Future Hold?
Faculty Biographies
James Spratt
Professor of Interventional Cardiology
Prof James Spratt is a Professor of Interventional cardiology. A high-volume Interventional Cardiologist with an international reputation in complex PCI, with a sub-speciality interest in intravascular imaging and CTO. Widely published within this area and has performed live case demonstrations globally. He is interested in medical education and is the Founder of Optima Education. Prof James Spratt is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).
Sanjog Kalra
Interventional Cardiologist
Dr Sanjog Kalra is an Interventional Cardiologist at University of Toronto, Toronto, CA.
He specialises in complex, high risk coronary revascularisation, chronic total occlusion and mechanical circulatory support.
Carlos Collet
Interventional Cardiologist
Dr Carlos Collet practices as an interventional cardiologist at Olv Hospital Aalst, Aalst, Belgium.
Dr Collet earned a doctorate in Cardiovascular Sciences from the University of Amsterdam. During his doctoral studies, he devoted his research to the integration of coronary imaging and physiology in patients with complex coronary artery disease.
He has published over 300 peer-reviewed articles and serves as the co-director of the catheterisation laboratory at the Cardiovascular Center OLV Aalst in Belgium.
Colm Hanratty
Interventional Cardiologist
Dr Colm Hanratty is an Interventional Cardiologist at Mater Private Hospital, Dublin, IE. Prior to joining Mater Private Hospital, he was clinical lead within the Belfast Trust for 8 years.
He has sub-specialty interest in the management of complex Percutaneous Coronary Intervention (PCI) and is internationally recognised as one of the leading interventionists in terms of complex and chronic total occlusion PCI.
Ziad A Ali
Dr Ali is a board-certified cardiologist specialising in interventional and structural cardiology at St Francis Hospital and Heart Center in Roslyn, New York.
Ziad is an internationally renowned expert in complex high-risk indicated percutaneous coronary interventions (CHIP) including the treatment of chronic total occlusions (CTO) where the arteries in the heart become completely blocked.
Ziad specialises in the management of cardiovascular disease in patients with pre-existing kidney disease.
Rasha Al-Lamee
Interventional Cardiology Consultant
Dr Rasha Al-Lamee is an interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, UK.
Dr Al-Lamee studied at the University of Oxford and University College London. She completed her training in clinical cardiology on the north-west London cardiology rotation in 2013, and completed her PhD at Imperial College London in 2018.
Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is lead author of the primary publication in The Lancet. Dr Al-Lamee has more than 50 peer-reviewed publications and has presented at international cardiology conferences worldwide.
Margaret B McEntegart
Director of Complex PCI and CTO Programmes
Dr Margaret McEntegart serves as the Director of Complex PCI and CTO programmes at Columbia University Irving Medical Center, New York, US. She also holds the role of Director of Cardiac Catheterization Laboratories at Columbia University Irving Medical Center / New York-Presbyterian Hospital.
Before joining Columbia, Dr McEntegart served as a consultant interventional cardiologist at Golden Jubilee National Hospital (UK), where she played a pivotal role in establishing and leading the CTO and Complex PCI Programme.
Kevin Croce
Interventional Cardiologist
Dr Kevin Croce is an Interventional Cardiologist and the director of the Chronic Total Occlusion Complex Percutaneous Coronary Intervention Program at Brigham and Women's Hospital, Boston, US.
His clinical interests include advanced treatments for obstructive coronary artery disease (CAD) and optimisation of antithrombotic and antiplatelet pharmacotherapy.
Dr Croce is the author of more than 50 peer-reviewed publications and his research focuses on understanding the molecular pathobiology of atherothrombotic (CAD) and on identifying new targets for CAD treatment.
Jonathan Hill
Dr Jonathan Hill qualified from Edinburgh University Medical School in 1992 following pre-clinical training at Cambridge University. He trained in cardiology at The London Chest and St Bartholomew's Hospitals.
In 1999 he was awarded the first National Heart, Lung and Blood Institute Bench to Bedside award and trained in basic science and interventional research within the Cardiovascular Branch of the National Institutes of Health in Bethesda. He completed his interventional cardiology training at the London Chest Hospital.
In 2005 he was appointed as Clinical Senior Lecturer and Consultant Cardiologist at King's College London.
Comments